Results 211 to 220 of about 166,859 (297)

Long‐Term Efficacy and Safety of Ligelizumab as Re‐Treatment in Patients With Chronic Spontaneous Urticaria

Allergy, EarlyView.
Ligelizumab re‐treatment in CSU patients showed sustained efficacy and tolerability. Over 50% achieved symptom control (UAS7 ≤ 6) by Week 12; benefits maintained through Week 52. No new safety signals observed; aligns with prior PEARL trial outcomes. CSU, chronic spontaneous urticaria; mg, milligram; q4w, every 4 weeks; UAS, urticaria activity score ...
Ana M. Gimenez‐Arnau, Marcus Maurer, Adam Reich, Chia‐Yu Chu, Diana Deleanu, Gordon Sussman, Jorge Sanchez, Knut Brockow, Koremasa Hayama, Michihiro Hide, Mohamed Denguezli, Raisa Meshkova, Roberta F. J. Criado, Sarbjit Saini, Solange Valle, Eva Hua, Pengpeng Wang, Alis Burciu, Isabelle Indermuehle, Vineeth Varanasi, Yolandi Joubert, Thomas Severin, Manmath Patekar   +22 more
wiley   +1 more source

Immunosenescence in Older Patients with Psoriasis: Mechanistic Insights and Opportunities for Biologic Therapy. [PDF]

Psoriasis (Auckl)
Wang W, Zha S, Sun L, Zhou D.
europepmc   +1 more source

A Case of Annular Pustular Psoriasis Possibly Triggered by Cabozantinib and Edoxaban During Nivolumab Therapy

The Journal of Dermatology, EarlyView.
Mana Nagatake, Hiroto Horikawa, Risa Kakuta, Takeya Adachi, Keishiro Fukumoto, Masayuki Amagai, Yoshihiro Ito   +6 more
wiley   +1 more source

Update on Non‐Biological and RNA‐Based Therapeutics in Chronic Inflammatory Diseases: Precision Medicine Through Small Molecules: An EAACI Position Paper

Allergy, EarlyView.
ABSTRACT In the last decades, critical advancements in research technology and knowledge on disease mechanisms steered therapeutic approaches for chronic inflammatory diseases towards unprecedented target specificity. For allergic and chronic lung diseases, biologic drugs pioneered this goal, acquiring on the way—through the clinical use of monoclonal ...
F. Roth‐Walter, I. M. Adcock, C. Benito‐Villalvilla, R. Bianchini, L. Bjermer, G. Caramori, L. Cari, K. F. Chung, Z. Diamant, I. Eguiluz‐Gracia, E. F. Knol, M. Jesenak, F. Levi‐Schaffer, G. Nocentini, L. O'Mahony, O. Palomares, F. Redegeld, M. Sokolowska, B. Van Esch, M. Zurlo, C. Stellato   +20 more
wiley   +1 more source

Systemic Immune-Inflammation Index (SII) as a Predictive Biomarker of Therapeutic Response in Psoriasis: A Retrospective Comparative Analysis of Anti-TNF, Anti-IL-17, and Anti-IL-23 Agents. [PDF]

J Pers Med
Trovato E, La Marca F, Simonini B, Dragotto M, Calandra E, Lussana F, Cartocci A, Rubegni P.   +7 more
europepmc   +1 more source

PSORIASIS AND ARTHRITIS [PDF]

Rheumatology, 1956
openaire   +3 more sources

A tissue-engineered human psoriatic skin model: targeting inflammation and glucose metabolism dysregulation in psoriasis using microneedle patches. [PDF]

Front Mol Biosci
Ruel Y, Moawad F, Cortez Ghio S, Brambilla D, Pouliot R.   +4 more
europepmc   +1 more source

Integrated Clinical Trial and Molecular Profiling Reveals Immune Drivers of Chronic Hand Eczema

Allergy, EarlyView.
This study performed an unbiased molecular profiling of CHE patients across diverse etiologies to identify shared pathogenic drivers and evaluate the impact of IL‐4Rα blockade via dupilumab over 16 weeks. CHE shows a mixed immune signature involving type 1, 2, and 3 pathways with features of atopic dermatitis and psoriasis.
Perrine Gery, Rüçhan Ekren, Emilie Bérard, Aurélie Du‐Thanh, Hugo Rimet, Fatma Jendoubi, Vanina Lenief, Nadia Raison‐Peyron, Amel Bouznad, Maria P. Konstantinou, Jonathan Rioual, Lilian Basso, Juliette Mouiren, Manon Boussier, Brigitte Milpied, Cristina Bulai Livideanu, Louise Jaulent, Florence Hacard, Marine A. Lefevre, Audrey Nosbaum, Julien Seneschal, Marc Vocanson, Carle Paul, Nicolas Gaudenzio, Marie Tauber, on behalf of the French Atopic Dermatitis Network from de GREAT Research group   +25 more
wiley   +1 more source

Bullous Pemphigoid Possibly Induced by Deucravacitinib in a Patient with Psoriasis. [PDF]

Clin Cosmet Investig Dermatol
Lu X, Zhang Y, Zhang H, Tang K, Jin H.
europepmc   +1 more source

Non‐Invasive Scalp Tape‐Strip RNA Sequencing Captures Disease Activity and Treatment‐Response Signatures in Alopecia Areata

Allergy, EarlyView.
Non‐invasive scalp tape‐strip RNA sequencing captures core immune and follicular molecular signatures in alopecia areata. Tape‐strip transcriptomic profiles reflect disease severity and treatment response to baricitinib, with concordance to scalp biopsy‐derived signatures.
Carmen Mochón‐Jiménez, Jesús Gay‐Mimbrera, Viviana Dávila‐Flores, Helen He, Jerry Zhou, Irene Rivera‐Ruiz, Pedro J. Gómez‐Arias, Juan de Luque‐Fernández, Benjamin Ungar, Emma Guttman‐Yassky, Juan Ruano   +10 more
wiley   +1 more source